Spondyloarthritis & psoriatic arthritis
Phenotypic differences and treatment persistence in a large multicentre cohort of axial psoriatic arthritis
Authors' conclusion
Treatment persistence in axial PsA varies according to clinical phenotypes, HLA-B27 status and pain
Study context
- Population
- Patients with axial psoriatic arthritis (PsA), large multicentre cohort
- Participants
- 621 patients
- Exposure
- Isolated axial PsA vs axial PsA+oligo vs axial PsA+poly
- Isolated axial PsAn = 175
- Axial PsA+oligon = 252
- Axial PsA+polyn = 194
- Outcome
- Persistence of first-line b/tsDMARDs
Methodological detailsmulticentre, Kaplan-Meier analysis, LASSO Cox regression
- Multicentre
- Kaplan-Meier analysis
- LASSO Cox regression
Main finding
As reported in the abstract
P = 0.006
Observational data: associations, not effects.
Further findings
Psoriasis · baseline — Isolated axial PsA and axial PsA+oligo vs Axial PsA+poly
P < 0.001
HLA-B27 positivity · baseline — Axial PsA+poly vs Isolated axial PsA and axial PsA+oligo
P = 0.02
Sacroiliitis · baseline — Isolated axial PsA and axial PsA+oligo vs Axial PsA+poly
P < 0.001
Spondylitis · baseline — Axial PsA+poly vs Isolated axial PsA and axial PsA+oligo
P < 0.001
Factors associated with discontinuation (shorter persistence)
- Higher VAS global pain: shorter persistence, aHR
- 1.010 (95% CI 1.003-1.018, P = 0.009)
- HLA-B27 positivity: longer persistence, aHR
- 0.56 (95% CI 0.32-0.99, P = 0.045)
Original publication
Composed by AI from the published abstract and checked against it. How Briefs are made →